{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:10:06Z","timestamp":1770815406396,"version":"3.50.1"},"reference-count":33,"publisher":"The Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,12,1]]},"abstract":"<jats:p>Introduction: Asoprisnil, a novel orally active selective progesterone receptor modulator, is being studied for the management of symptomatic uterine leiomyomata. The exact mechanism of action is not yet discerned. The primary objectives of this double-blind, randomized, placebo-controlled study included evaluation of the effect of asoprisnil on uterine artery blood flow. Furthermore, we assessed effects of asoprisnil on leiomyoma symptoms.<\/jats:p>\n               <jats:p>Patients and Methods: Thirty-three premenopausal patients scheduled for hysterectomy due to symptomatic uterine leiomyomata were recruited in four centers and treated with 10 or 25 mg asoprisnil or placebo for 12 wk before surgery. At baseline and before hysterectomy, all patients underwent sonographic assessment to measure impedance to uterine artery blood flow, determined by resistance index and pulsatility index, as well as volumes of largest leiomyoma and uterus. In addition, patients recorded intensity and frequency of menstrual bleeding on a menstrual pictogram. Each asoprisnil treatment was compared with placebo.<\/jats:p>\n               <jats:p>Results: The increased pulsatility index in both asoprisnil groups and the statistically significantly increased resistance index within the 25-mg asoprisnil group suggest a moderately decreased uterine artery blood flow. Analysis of menstrual pictogram scores showed a statistically significant larger decrease in frequency and intensity of bleeding for both asoprisnil groups compared with placebo. Bleeding was suppressed by asoprisnil 25mg in 91% of patients. Asoprisnil treatment was well tolerated when administered daily for a 12-wk period, and no serious adverse events occurred.<\/jats:p>\n               <jats:p>Conclusion: Asoprisnil moderately reduced uterine artery blood flow. This effect may contribute in part to the clinical effects of asoprisnil.<\/jats:p>","DOI":"10.1210\/jc.2008-1104","type":"journal-article","created":{"date-parts":[[2008,9,3]],"date-time":"2008-09-03T00:54:34Z","timestamp":1220403274000},"page":"4664-4671","source":"Crossref","is-referenced-by-count":79,"title":["Effects of the Selective Progesterone Receptor Modulator Asoprisnil on Uterine Artery Blood Flow, Ovarian Activity, and Clinical Symptoms in Patients with Uterine Leiomyomata Scheduled for Hysterectomy"],"prefix":"10.1210","volume":"93","author":[{"given":"Julia","family":"Wilkens","sequence":"first","affiliation":[{"name":"Centre for Reproductive Biology (J.Wi., H.O.D.C.), University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristof","family":"Chwalisz","sequence":"additional","affiliation":[{"name":"TAP Pharmaceutical Products Inc. (K.C., C.H.), Lake Forest, Illinois 60045"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Han","sequence":"additional","affiliation":[{"name":"TAP Pharmaceutical Products Inc. (K.C., C.H.), Lake Forest, Illinois 60045"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Walker","sequence":"additional","affiliation":[{"name":"Royal Infirmary (J.Wa.), Edinburgh EH16 4SA, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iain T.","family":"Cameron","sequence":"additional","affiliation":[{"name":"Developmental Origins of Health and Disease Division (DoHaD) (I.T.C., S.I., A.C.L.), University of Southampton, Southampton SO16 6YD, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Ingamells","sequence":"additional","affiliation":[{"name":"Developmental Origins of Health and Disease Division (DoHaD) (I.T.C., S.I., A.C.L.), University of Southampton, Southampton SO16 6YD, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra C.","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Developmental Origins of Health and Disease Division (DoHaD) (I.T.C., S.I., A.C.L.), University of Southampton, Southampton SO16 6YD, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ann","family":"Lumsden","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology (M.A.L.), University of Glasgow, Glasgow G37 2ER, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dharani","family":"Hapangama","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology (D.H.), University of Liverpool, Liverpool L8 7SS, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alistair R. W.","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Pathology (A.R.W.W.), University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilary O. D.","family":"Critchley","sequence":"additional","affiliation":[{"name":"Centre for Reproductive Biology (J.Wi., H.O.D.C.), University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071614010873000_R1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(00)03622-9","article-title":"Uterine fibroids.","volume":"357","author":"Stewart","year":"2001","journal-title":"Lancet"},{"key":"2020071614010873000_R2","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1289\/ehp.5787","article-title":"Etiology and pathogenesis of uterine leiomyomas: a review.","volume":"111","author":"Flake","year":"2003","journal-title":"Environ Health Perspect"},{"key":"2020071614010873000_R3","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1136\/bmj.330.7506.1457","article-title":"Hysterectomy for benign conditions.","volume":"330","author":"Edozien","year":"2005","journal-title":"BMJ"},{"key":"2020071614010873000_R4","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1056\/NEJMoa062003","article-title":"Uterine-artery embolization versus surgery for symptomatic uterine fibroids.","volume":"356","author":"Edwards","year":"2007","journal-title":"N Engl J Med"},{"key":"2020071614010873000_R5","first-page":"1","article-title":"Hysterectomy surveillance: United States, 1980\u20131993.","volume":"46","author":"Lepine","year":"1997","journal-title":"MMWR CDC Surveill Summ"},{"issue":"Suppl 5","key":"2020071614010873000_R6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1289\/ehp.00108s5791","article-title":"Advances in uterine leiomyoma research: the progesterone hypothesis","volume":"108","author":"Rein","year":"2000","journal-title":"Environ Health Perspect"},{"key":"2020071614010873000_R7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0039-128X(00)00171-9","article-title":"Effects of progesterone on uterine leiomyoma growth and apoptosis.","volume":"65","author":"Maruo","year":"2000","journal-title":"Steroids"},{"key":"2020071614010873000_R8","first-page":"1439","article-title":"A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin \u201cadd-back\u201d regimens for women with leiomyomata uteri.","volume":"76","author":"Friedman","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614010873000_R9","first-page":"243","article-title":"Low-dose mifepristone for uterine leiomyomata.","volume":"101","author":"Eisinger","year":"2003","journal-title":"Obstet Gynecol"},{"key":"2020071614010873000_R10","first-page":"1627","article-title":"The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study","author":"Reinsch","year":"1994","journal-title":"Am J Obstet Gynecol 170:1623\u20131627; discussion"},{"key":"2020071614010873000_R11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1210\/er.2005-0001","article-title":"Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis.","volume":"26","author":"Chwalisz","year":"2005","journal-title":"Endocr Rev"},{"key":"2020071614010873000_R12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1055\/s-2005-864034","article-title":"Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11\u03b2-benzaldoxime substituted selective progesterone receptor modulators (SPRMs).","volume":"23","author":"Schubert","year":"2005","journal-title":"Semin Reprod Med"},{"key":"2020071614010873000_R13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0039-128X(00)00178-1","article-title":"Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity.","volume":"65","author":"Elger","year":"2000","journal-title":"Steroids"},{"key":"2020071614010873000_R14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2004-828617","article-title":"Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata.","volume":"22","author":"Chwalisz","year":"2004","journal-title":"Semin Reprod Med"},{"key":"2020071614010873000_R15","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.fertnstert.2006.11.094","article-title":"A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata.","volume":"87","author":"Chwalisz","year":"2007","journal-title":"Fertil Steril"},{"key":"2020071614010873000_R16","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/humrep\/dem026","article-title":"The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata.","volume":"22","author":"Williams","year":"2007","journal-title":"Hum Reprod"},{"key":"2020071614010873000_R17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1046\/j.1469-0705.1996.07020129.x","article-title":"Intraobserver reproducibility of transvaginal Doppler measurements in uterine and intraovarian arteries in regularly menstruating women.","volume":"7","author":"Tekay","year":"1996","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2020071614010873000_R18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1469-0705.2001.00399.x","article-title":"Intraobserver reproducibility of Doppler measurements of uterine artery blood flow velocity in premenopausal women.","volume":"17","author":"Valentin","year":"2001","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2020071614010873000_R19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejogrb.2003.10.027","article-title":"Uterine fibroids: do size and location determine menstrual blood loss?","volume":"115","author":"Sulaiman","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2020071614010873000_R20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0015-0282(01)01847-7","article-title":"Determination of total menstrual blood loss.","volume":"76","author":"Wyatt","year":"2001","journal-title":"Fertil Steril"},{"key":"2020071614010873000_R21","first-page":"290","article-title":"The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata.","volume":"99","author":"Spies","year":"2002","journal-title":"Obstet Gynecol"},{"key":"2020071614010873000_R22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/oxfordjournals.humrep.a137553","article-title":"Effect of cyclofenil on hormonal dynamics, follicular development and cervical mucus in normal and oligomenorrhoeic women.","volume":"7","author":"Yong","year":"1992","journal-title":"Hum Reprod"},{"key":"2020071614010873000_R23","doi-asserted-by":"crossref","first-page":"E521","DOI":"10.1152\/ajpendo.00381.2002","article-title":"Assessing menstrual cycles with urinary hormone assays","volume":"284","author":"Santoro","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071614010873000_R24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1210\/jcem.87.1.8140","article-title":"Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days.","volume":"87","author":"Brown","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614010873000_R25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s004040050227","article-title":"Uterine artery Doppler velocimetry with leiomyomas.","volume":"262","author":"Farmakides","year":"1998","journal-title":"Arch Gynecol Obstet"},{"key":"2020071614010873000_R26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0020-7292(03)00127-9","article-title":"Doppler-ultrasound as a predictor of uterine fibroid response to GnRH therapy.","volume":"82","author":"Kanelopoulos","year":"2003","journal-title":"Int J Gynaecol Obstet"},{"key":"2020071614010873000_R27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0015-0282(99)00161-2","article-title":"Altered uterine artery blood flow impedance after danazol therapy: possible mode of action in dysfunctional uterine bleeding.","volume":"72","author":"Pepper","year":"1999","journal-title":"Fertil Steril"},{"key":"2020071614010873000_R28","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1210\/jc.2005-2379","article-title":"A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells.","volume":"91","author":"Chen","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614010873000_R29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1933719107311464","article-title":"Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells.","volume":"14","author":"Ohara","year":"2007","journal-title":"Reprod Sci"},{"key":"2020071614010873000_R30","first-page":"1217","article-title":"An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial.","volume":"76","author":"Carr","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614010873000_R31","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/humrep\/deh738","article-title":"The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women.","volume":"20","author":"Chwalisz","year":"2005","journal-title":"Hum Reprod"},{"key":"2020071614010873000_R32","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/0002-9378(90)90667-V","article-title":"Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.","volume":"163","author":"Friedman","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"2020071614010873000_R33","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.ajog.2003.11.016","article-title":"Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia?","volume":"190","author":"Warner","year":"2004","journal-title":"Am J Obstet Gynecol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/12\/4664\/9053405\/jcem4664.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/12\/4664\/9053405\/jcem4664.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T01:11:37Z","timestamp":1594948297000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/93\/12\/4664\/2627294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,1]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2008-1104","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,1]]}}}